Ranbaxy receives approval to mkt Cefprozil tablets, powder

Published on Thu, Apr 12, 2007 at 14:51 |  Source : Moneycontrol.com

Updated at Thu, Apr 12, 2007 at 16:57  

39737 Investors following Ranbaxy Labs. Share this News with them.
0
0
Share on Tumblr

RELATED NEWS

ALSO READ

Ranbaxy Laboratories Limited (RLL), announced today that the Company has received approval to manufacture and market RAN™-Cefprozil Tablets, 250mg and 500mg, and RAN™-Cefprozil  Powder for Oral Suspension, 250mg/5mL from Health Canada.  The total market size for Cefzil™* in Canada was CAD 28.2 million dollars (IMS-MAT: Dec 2006). 

 

Cefprozil Tablets and Powder for Oral Suspension are indicated for the treatment of upper respiratory tract infections, uncomplicated skin and urinary tract infections.

 

"We are pleased to receive these approvals for RAN™-Cefprozil, Tablets and Powder for Oral Suspension to expand the number of product offerings that Ranbaxy commercializes for use by patients who require the therapeutic benefits of this product where indicated.  This further adds to our expanding generic product portfolio which will have benefits of offering an affordable generic alternative to the brand that will now be accessible to all Canadians,"  according to Bill Abboud, President, RPCI.

 

Ranbaxy Pharmaceuticals Canada Inc ., (RPCI) based in Mississauga, Ontario, Canada, is a wholly subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company.  RPCI is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system.

 

Sourced From: Ranbaxy Laboratories Ltd

  

Trending News

Business News

Sony to roll-out ICS update next week, Xperia PLAY gets the boot
Reebok execs named in Rs 870 cr fraud denied anticipatory bail "Reebok execs named in Rs 870 cr fraud denied anticipatory bail"

Live Updates: KKR favourites in last-over battle

Rel Comm Q4 Cons Net Revenue Up 5% At `5,310 Cr (QoQ)

The latest earning numbers FIRST on CNBC-TV18
Videos

May 25 2012, 22:26

NHPC posts profit amid capacity addition, delay woes

- in Results Boardroom

Interviews

May 27 2012, 11:52 | Source: CNBC-TV18

Expect to maintain EBIDTA margin ahead: Wockhardt  

May 27 2012, 11:00 | Source: CNBC-TV18

e-commerce market in India: What's in store?  

Subscribe to

Moneycontrol Newsletters

Moneycontrol.com offers you a choice of various sectoral and other newsletters for FREE!